All In Biotech

Drug Trial Radar · NCT04508244

Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status

Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status: A Randomized Controlled Trial (BBTBBT)

Last checked: Nov 20, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 771 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

771

Planned (sponsor's estimate)

Start

Dec 29, 2020

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Hamad Medical CorporationIndustry
Sponsor type
Industry
First posted
Aug 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Beta blockers (BB) play an important role in protection of end organs that are susceptible for secondary injury by the Traumatic brain injury (TBI)-induced catecholamine surge. However, use of BBs in trauma patients is not yet the standard of care which necessitates clear scientific evidence and justification to be used especially in TBI patients. The BBTBBT study aims to determine whether early administration of propranolol based on the HSTnT status will improve the outcome of mild-to-severe TBI patients. Our primary hypothesis is that BBs are effective in reducing 10 and 30-day mortality in TBI patients.BBs are effective in reducing 10 and 30-day mortality in TBI patients. Methods/Design: The BBTBBT study is a prospective, randomized, double-blinded, placebo-controlled trial, three-arm trial of BB use in mild-to-severe TBI patients based on the HsTnT status.

Conditions

  • Trauma
  • Brain Injuries
  • Stress Reaction
  • Beta Blockers
  • Troponin

Interventions

  • PlaceboDrug

    12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.

  • PropranololDrug

    12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 \& 4 and 1 ampoule/day for day-5 \& 6.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MortalityTime frame: 10 days
  2. MortalityTime frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hamad General Hospital

    Doha, Qatar · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.